Introduction
Global developmental delay is defined as significant delay in two or more developmental domains: gross or fine motor, speech/language, cognitive, social/personal, and activities of daily living, and is thought to predict a future diagnosis of intellectual disability [1] . Such delays require accurate documentation using norm-referenced and age-appropriate standardized measures of development administered by experienced developmental specialists [2] . The term 'global developmental delay' is usually reserved for younger children (i.e. typically less than 5 years of age) while the term 'intellectual disability' is usually applied to older children when intelligence quotient (IQ) testing is valid and reliable [3] . Children with developmental delays are those who present with delays in the attainment of developmental milestones at the expected age. The term implies deficits in learning and adaptation, suggesting that the delays are significant and predict later disability. Delays in development, however, especially those that are mild, may be transient and lack predictive reliability for intellectual disability.
Intellectual disability is a lifelong disability presenting in infancy or the early childhood years which cannot be diagnosed until the child is at least 5 years old, when standardized measures of developmental skills become reliable and valid. There are many definitions of intellectual disability, but the four most frequently used are: the American Association on Mental Retardation (AAMR) 1992 definition; the Diagnostic and Statistical Manual (DSM IV) 1994 definition; The International Classification of Diseases, 10th edition (ICD-10); and the American Psychological Association 1996 definition. The American Association on Intellectual and Developmental Disability defines intellectual disability by measures of three domains: IQ, adaptive behavior and systems of supports. Thus, one cannot rely solely upon the measure of IQ to define intellectual disability [4] . More recently, the term 'intellectual disability' has been suggested to replace 'mental retardation' [5] . Of these, the AAMR definition is the most used in the USA and the ICD-10 definition is the most used outside the USA [6] . The prevalence of intellectual disability is estimated at 1-3% [6] .
Schaefer and Bodensteiner [7] define diagnosis as that which 'can be translated into useful clinical information for the family, including providing information about prognosis, recurrence risks, and preferred modes of available therapy'. Van Karnebeek et al. [8] define etiologic diagnosis as 'sufficient literature evidence . . . to make a causal relationship of the disorder with MR [mental retardation] likely, and if it met the Schaefer-Bodensteiner definition'.
The etiology of global developmental delay is highly heterogeneous and estimates of the etiologic yield (10-81%) in children with global developmental delay or intellectual disability are highly variable, with genetic etiology proved or suspected in the majority [9] . The most often quoted yield for the diagnostic evaluation is in the range of 40-60% [9] . The variability in diagnostic yield can be attributed to differences in a variety of factors including sample population characteristics, severity of delay in the children studied, extent of diagnostic investigations, and technological advances over time especially with respect to genetic and neuroimaging techniques.
The guidelines published by the American College of Medical Genetics (ACMG) [9] , the American Academy of Pediatrics (AAP) [10] , and the American Academy of Neurology (AAN) Child Neurology Society [11] generally agree on the evaluation process for children with global developmental delay or idiopathic intellectual disability. The diagnostic evaluation should be done by an expert clinician and consist of a comprehensive medical history, three-generation family history, dysmorphological examination and neurological evaluation. The judicious use of brain magnetic resonance imaging (MRI) is important, especially in those cases with microcephaly, macrocephaly or specific findings on neurological examination [9] [10] [11] . When a specific diagnosis is suspected, proper chromosome study or molecular genetic study for confirmation is appropriate. If no diagnosis is suspected, the clinician is recommended to obtain a standard karyotype, fluorescent in-situ hybridization (FISH) analysis for subtelomere abnormalities and molecular genetic testing for fragile X syndrome in all patients. In a systematic review of the literature, van Karnebeek et al. [12] reported a very high yield from the dysmorphological examination ranging from 39% to 81%. They reported the following yields: cytogenetics 9.5%, fragile X studies 2.0% (cytogenetic fragile X study yield of 5.4%), metabolic studies 1%, neurological examination 42.9%, neuroimaging studies 30% for abnormalities and 1.3% for an etiology, and dysmorphological examination ranging from 39% to 81%. Based on this systematic literature review, van Karnebeek et al. suggest that diagnostic evaluation of the child with global developmental delay or intellectual disability should include the following: (1) detailed clinical history, neurological exam and dysmorphological exam; (2) standard cytogenetics irrespective of setting, degree of intellectual disability and presence or absence of dysmorphological features; (3) FISH analysis for subtelomere rearrangements only when checklists (e.g. that of De Vries et al. [13] ) are indicative of high yield; and (4) molecular genetic studies for fragile X syndrome in all boys but only in girls when family history or dysmorphological exam is suggestive. They also argue that metabolic studies should not be done as the first tier of diagnostic studies but should be considered if no diagnosis is made or if suggestive signs or symptoms are present. In addition, they note that neuroradiological imaging has a high rate of detection of abnormalities but a low yield in establishing an etiologic diagnosis, hence neuroimaging is indicated if there is high suspicion for abnormality including macro or microcephaly, focal findings on neurological examination, seizures or other symptoms or signs suggestive of brain anomalies; brain MRI is better than computed tomography.
The recommendations of the AAP, AAN and ACMG will need to be updated to address the improved diagnostic yield with appropriate use of array comparative genomic hybridization (aCGH) and replace the FISH subtelomere testing recommendation with that of aCGH use. It has been estimated that 5% of cases of global developmental delay have been diagnosed by clinically-applied highresolution standard karyotype and around another 5% by FISH for subtelomere rearrangements. There appears to be an additional 10% diagnostic yield from aCGH diagnostic studies of patients who have idiopathic intellectual disability and who have had normal karyotype and normal FISH for subtelomere abnormalities. This is a significant advance for the diagnostic evaluation of children with global developmental delay or intellectual disability, and may aid in the discovery of new syndromes and new genes that cause disability.
Array comparative genomic hybridization
Subtelomere FISH investigations appear to be becoming a second-line or confirmatory diagnostic method in the patient with idiopathic developmental delay, having been replaced in the initial evaluation by the newer aCGH techniques [14] [15] [16] . aCGH compares DNA content from two differentially labeled genomes: the patient and the control. The two genomes are cohybridized, usually onto a glass microscope slide on which cloned or synthesized DNA fragments have been immobilized. Arrays have been built with a variety of DNA substrates that may include oligonucleotides, complementary DNAs and bacterial artificial chromosomes (BACs). The arrays might be whole genome arrays which are designed to cover the entire genome, or targeted arrays which target known pathological loci, the telomeres (similar to the use of FISH subtelomere probes) and pericentromeric regions. The primary advantage of aCGH over FISH is the array's ability to detect DNA copy changes simultaneously at multiple loci in a genome in one 'experiment' or test. These copy number changes may include deletions, duplications or amplifications at any locus, as long as that region is represented on the array. aCGH might be thought of as a FISH test over hundreds or even thousands of loci in one test sample. aCGH, independent of whether it is 'whole genome' or 'targeted' and what type of DNA substrate (oligonucleotide, cDNA or BAC), identifies deletions and/or duplications of chromosome material with a high degree of sensitivity in a more efficient manner than FISH techniques. The FISH test is currently used in clinical practice predominantly to confirm a clinical diagnosis whereas aCGH does not require an expert clinician to suspect a specific diagnosis (e.g. Smith-Magenis syndrome). The resolution of aCGH is determined by the size of the nucleic acid targets and the density of coverage over the genome. The smaller the size of the nucleic acid targets and the more contiguous the targets on the native chromosome, the higher the resolution of the array. The level of resolution is nearly limitless depending on the size of the arrayed probes and the distance between. In addition, 'tiling arrays' covering the entire genome ensure there are no gaps in the array [17] .
Copy number variations in the human genome
Sebat et al. [18] and Iafrate et al. [19] both reported on the surprisingly large number of large genomic duplications and deletions in the human genome. It now known that large segments of DNA, varying from thousands to millions of bases in length, can vary in copy number and that such copy number variations (CNVs) can encompass genes leading to dosage imbalances [20] . Using a tiling-path BAC array together with 550 k oligonucleotide single nucleotide polymorphism (SNP) genotyping arrays to compare genomes of 270 individuals from different populations, these authors identified 1447 CNVs occurring across about 12% of the entire genome comprising some 2900 genes, or 10% of the total. CNVs can cause genomic disorders through genomic rearrangements in which the phenotype results from abnormal dosage of the gene or genes [20] . The use of aGCH is complicated by the fact that some CNVs, particularly those identified by arrays using whole genome tiling oligonucleotide methods, will identify a significant number of variants (deletions or duplications) of unknown significance. There are international databases in place to address this problem. For example, the DECIPHER database (http://www.sanger.ac.uk/PostGenomics/decipher/) is designed to collect phenotype information matched with aCGH genotype in an effort to improve genetic healthcare and gene discovery . Another is the Copy Number Variation Project (http://www.sanger.ac.uk/humgen/cnv/) which is characterizing 'functionally-relevant CNVs at as high resolution as possible, incorporating these variants within association studies for complex diseases, and developing a public resource to facilitate integration of CNV within medical genetic studies'.
Recent reports on the application of aCGH to the evaluation of individuals with intellectual disability
Thirteen recent clinical studies support the use of aCGH in diagnostic evaluation, and are reporting a range of diagnosis from 4.2% to 20%. These studies vary by patient selection selection criteria, including: whether they have had previous karyotype or FISH for subtelomere abnormalities or specific known syndromes; by array design, with most being BAC or oligonucleotide arrays; and by the density of genome coverage (whole genome or targeted arrays). Vissers et al. [21] evaluated 20 patients with intellectual disability who had had a normal standard karyotype using a whole genome aCGH and identified four patients (20%) with a deletion or duplication causal of the disability. Shaw-Smith et al. [22] investigated 50 patients with mental retardation and dysmorphic features using a whole genome cDNA aCGH and identified 12 (24% of the total sample) patients with deletions or duplications, of which five were seen in phenotypically normal parents. Thus, the aCGH led to diagnosis in five cases, or 14% of the sample. Likewise, Schoumans et al. [23] evaluated 41 children with 'idiopathic mental retardation and dysmorphic features' using a commercially available genome-wide aGCH using BAC clones. From this sample, four children were diagnosed with pathologic deletions (9.8%). Tyson et al. [24] evaluated 22 individuals with mild to moderate intellectual disability using a commercially available whole genome aCGH and identified two patients with abnormalities, one with duplication and one deletion. De Vries et al. [17] evaluated 100 individuals with intellectual disability by whole genome aCGH to find seven with deletions and three duplications (10% of sample) that were diagnostic. Shaffer et al. [25] reported their experience in 1500 consecutive cases that were submitted to one laboratory for array evaluation. The targeted array used detected genomic abnormalities in 9% of patients referred for a multitude of problems that included developmental delay, dysmorphic features, and a variety of birth defects: 134 (8.9%) showed a genomic abnormality, 36 (2.4%) showed polymorphisms or familial variants, 14 (0.9%) showed alterations of unknown clinical significance, and 84 (5.6%) showed clinically relevant genomic alterations. These included subtelomeric deletions and unbalanced rearrangements, microdeletions and reciprocal duplications, rare abnormalities, and low-level trisomy mosaicism. This is the first large study by one reference laboratory on the outcomes of 1500 samples from patients Evaluating children with developmental delay Moeschler 119 with global developmental delay, dysmorphic features and congenital malformations. In a group of 30 individuals with mental retardation and dysmorphic features, Miyake et al. [26] found five aCGH abnormalities using a whole genome BAC clone approach among a sample of 30 individuals with intellectual disability. Two of the five were subtelomeric in location. In addition, they identified 22 copy number abnormalities that were not pathological. In the largest study to date of a well-characterized sample of individuals with idiopathic mental retardation, Menten et al. [27] reported on a sample of 140 patients of whom 28 (20%) had abnormal aCGH using a whole genome BAC array. Of these, 17 (12.1%) had abnormalities detected, 11 of which had had prior FISH subtelomere testing that was normal. Sharp et al. [28] studied 290 individuals with intellectual disability using a constructed segmental duplication BAC array targeting 'rearrangement hot spots'. They identified 14 (4.8%) with abnormalities including four who had a new microdeletion syndrome, 17q21.31 deletion syndrome, thought to contain the MAPT gene; this was postulated to be causal of the disability. Rosenberg et al. [29] evaluated 81 individuals with intellectual disabilities with an array of 3500 oligonucleotides spaced at 1 Mb intervals across the entire genome to find that 13 (16%) had abnormalities considered causal of the disability. There were several who had CNVs thought to be benign (inherited from a parent without the phenotype). Hoyer et al. [30 ] used a SNP genome-wide array on 104 unselected individuals with mental retardation of whom 10 (9.1%) patients had abnormalities detected. Their use of a SNP microarray, however, identified a number of genomic aberrations that were not the cause of the patients' phenotype and were considered polymorphisms. Engels et al. [31 ] reported on a series of 60 individuals with unexplained intellectual disability using a genome-wide oligonucleotide aCGH. Of those, six abnormal imbalances were found (10%), all of whom had dysmorphic facial features. Thus, it appears from these studies that the role of aCGH is important in the evaluation of the child with developmental delay or intellectual disability.
New deletion and duplication syndromes and genes causing intellectual disability
The aCGH techniques will identify known syndromes such as Williams syndrome, velo-cardio-facial syndrome and Angelman syndrome in those patients who would be positive on FISH testing and also will identify those patients with subtelomere imbalances identified on the FISH testing. aCGH is effective in identifying those common syndromes associated with genomic deletions and with subtelomere abnormalities. It has also identified new syndromes not seen on standard karyotype or with FISH techniques. For example, in their study of 290 individuals with intellectual disability, Sharp et al. [28] identified microdeletion of 1.4 Mb of chromosome 17q21.31 in four individuals. This same 17q21.31 microdeletion syndrome was identified by two other groups [32] [33] [34] using somewhat different tiling microarrays to identify two candidate genes within the deleted region -MAPT and CRHR1 -that might be responsible for as much as 1% of all intellectual disability. This method of gene discovery has been successful in identifying CHD7 as the gene that causes the CHARGE syndrome [37] . Subtelomeric deletions of 22q13 are being identified relatively often [27, 32] . Some patients with this deletion present with global developmental delay and autistic behaviors. Duplications in the most common Rett syndrome gene (MECP2) are being identified in males with global developmental delays [35] . Barber et al.
[36 ] identified a new syndrome, 8p23 duplication, which is transmitted from parent to child, suggesting that some transmitted abnormalities on aCGH are pathological and that underappreciation for some syndrome diagnosis is likely.
X-linked intellectual disability syndromes and autism
Lugtenberg et al. [37] created a set of 1460 overlapping BAC clones spanning the entire X-chromosome among 40 families with nonsyndromic intellectual disability, and identified three individuals (Xp22.2 duplication in one; two with Xq28 duplication encompassing MECP2 gene). It may be that we will see clinical arrays soon that target patients with undiagnosed X-linked syndromes.
Regarding those patients with global developmental delay and a specific diagnosis of autism or, more commonly perhaps, those who have 'autistic features', there may be abnormalities on aCGH. A wide range of chromosomal disorders have been associated with autism. Those most commonly seen were 2qter deletion, 22qter deletion and 15q11-q13 (the Prader-Willi/Angelman region) duplication [38, 39] . These will be identified by microarrays now clinically available. A recent report [40 ] using whole genome association and aCGH in a series of 751 patients with autism identified a novel, recurrent microdeletion and a reciprocal microduplication at 16p11.2 that carry substantial susceptibility to autism and appear to account for approximately 1% of cases.
Future considerations
Microarrays have begun to replace the use of FISH in the evaluation of patients with global developmental delay. The use of aCGH will contribute as much as 10% to the diagnostic whole. There will be many 'false positives' that will require interpretation by the clinical geneticist or other expert clinician evaluating the child with global developmental delays. In the future, we will see studies that examine the clinical utility and efficiency of an array of different arrays.
Conclusion
The literature supports that aCGH is becoming an important diagnostic tool for the clinical evaluation of children or adults with developmental delays or intellectual disabilities. The problem of discriminating between a benign polymorphism and a true pathological genomic abnormality is challenging as it often requires an existing body of literature regarding the genomic finding, genetic counseling time and parental samples. As the DNA substrate becomes smaller with little distance between each DNA fragment, this task of interpretation by the expert clinician will be particularly challenging. Which type of array with what coverage of the genome best serves the patient and diagnostician currently remains an open question and a moving target. For the near future there is a real problem of 'false negative' and 'false positive' interpretations. Nevertheless, this is a substantial improvement in the ability to establish a diagnosis for patients and families and one that is expected to improve in the coming few years.
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